HK Stock Market Move | GENSCRIPT BIO (01548) is now up over 6%. CARVYKTI's fourth quarter trade sales net amount is approximately 3.34 billion US dollars.

GENSCRIPT BIO (01548) has surged over 6%, as of press time, up 6.25% to HKD 10.88, with a turnover of HKD 54.812 million. On the news front, GENSCRIPT BIO announced that its subsidiary Legend Biotech generated a net trade sales of approximately USD 334 million for the fourth quarter ending in December, representing a 16.8% increase over the previous quarter, under the cooperation and licensing agreement with Janssen. In addition, an official from the National Healthcare Security Administration stated that the first version of the Category B medical insurance list will be released by 2025. CICC International pointed out that the Category B list may prioritize drugs that have passed formal reviews and expert evaluations in China but have not been included in the basic medical insurance list, such as CAR-T and ADC therapies. This could potentially open up payment opportunities for domestic innovative drugs.